Abstract presentations

 

Paper ref #TypePaper TitleFirst NameLast NameOrganisation
1oralPrediction of Capecitabine induced Severe Toxicity using Machine Learning TechniquesMaëlSteunouSMARTc, Aix Marseille Univ
2oralLong term pemetrexed-based cancer treatment leads to nephrotoxicity NikkiDe RouwRadboudumc
3oralEpigenetic Regulation of OCTN1-mediated Cytarabine Transport in Acute Myeloid Leukemia JasonAndersonThe Ohio State University
4oralComprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patientsWesleyVan De GeerErasmus Mc / Translational Pharmacology
5oralQuantitative modeling of inter-lesion and inter-organ variability of tumor sizeSreenathM KrishnanUppsala University
6oralPopulation pharmacodynamics modelling of circulating lymphocyte count over time in chronic lymphocytic leukemia patients under ibrutinib treatmentFannyGallaisPaul Sabatier University Of Toulouse / Inserm Umr 1037
7oralPharmacokinetics and safety of pazopanib in frail elderly patients.FélicienLe LouedecInstitut Universitaire Du Cancer Toulouse
8oralPopulation pharmacokinetic and pharmacogenetic analysis of mitotane in adrenocortical carcinoma patients: towards individualized dosingAnyueYinLUMC
9oralModulation of CYP3A activity to increase the oral bioavailability of ibrutinibEricEisenmannThe Ohio State University
10oralEffects of dietary restriction in cancer patients receiving irinotecan.RubenVan EerdenErasmus Mc
11oralInfluence of probenecid on the pharmacokinetics and pharmacodynamics of sorafenibKoenHussaartsErasmus MC
12oralCorrelation between sunitinib exposure and toxicity in a real-life patient cohortKimWesterdijkDepartment of Medical Oncology, Radboud University Medical Centre
13posterComparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax studyRubenVan EerdenErasmus MC
14posterDeveloping drug delivery system for ASO in prostate cancer: preliminary resultsGuillaumeSicardSMARTc, Aix Marseille Univ
15posterClinical pharmacoloGy of platinUm-based hyperThermic intraperitoneal chemotherapy: exploration of the impact of flushing on tumOur, systemic and personnel eXposure
(GUTOX)
LoekDe JongRadboudumc
16posterInfluence of cow’s milk on the absorption and exposure of erlotinib in NSCLC patientsMarijnVeermanErasmus Mc
17posterInvestigation of Age-Dependency in Ewing Sarcoma Induction Therapy Using a Population Pharmacokinetic Modelling ApproachFarinaHellmannDepartment of Pharmaceutical and Medical Chemistry, Westfälische Wilhelms-Universität Muenster
18posterPrecision medicine in hematology-oncology: CDA as a predictive marker for Cytarabine exposure in AML patientsMelanieDonnetteSMARTc, Aix Marseille Univ
19posterInfluence of genetic variation in COMT on cisplatin-induced nephrotoxicity in cancer patients. BramAgemaErasmus MC
20posterPharmacokinetics of Mitomycin-c Lipidic Prodrug Entrapped in Liposomes (Promitil) and Clinical Correlations in Metastatic Colorectal Cancer Patients AlbertoGabizonShaare Zedek MC and Hebrew University
21posterQuantification of the tyrosine kinase inhibitor erlotinib in human scalp hair by liquid chromatography-tandem mass spectrometry: Pitfalls for clinical applicationLouwrensBraalErasmus MC
22posterThe impact of gastric acid suppressive agents on pazopanib exposureFloorLubbermanRadboudumc
23posterScreening for Potential Drug Interactions of TKIs with OATP1B1DominiqueGarrisonThe Ohio State University
24posterBiomarker-based dose individualisation of axitinib in metastatic renal cell carcinoma (mRCC): A simulation frameworkMaddalenaCentanniUppsala University
25posterThe impact of renal function on pemetrexed pharmacokinetics: implications for dosing in patients with impaired renal function.NikkiDe RouwRadboudumc
26posterPopulation pharmacokinetic model of sorafenib and application to therapeutic drug monitoring Ba HaiLESMARTc, Aix Marseille Univ
27posterPopulation pharmacokinetic model of sorafenib and application to a case reportBa HaiLEAmu
28posterApplication of the Optimal Design Approach to improve Therapeutic Drug Monitoring of Busulfan in Children receiving Hematopoietic stem cell transplantation (HSCT)BelénPérez SolansUniversity Of Navarra
29posterPopulation pharmacokinetic model of irinotecan and its four main metabolites in patients treated with FOLFIRI or FOLFIRINOX regimenLaureDeymeSMARTc, Aix Marseille Univ